PD59-02 HIGH DIMENSIONAL PROFILING OF THE IMMUNE MICROENVIRONMENT IN PROSTATE CANCER REVEALED NOVEL TUMOR-DRIVEN ALTERATIONS IN INFILTRATING SUBSETS

Abstract

You have accessJournal of UrologyProstate Cancer: Basic Research & Pathophysiology III (PD59)1 Apr 2020PD59-02 HIGH DIMENSIONAL PROFILING OF THE IMMUNE MICROENVIRONMENT IN PROSTATE CANCER REVEALED NOVEL TUMOR-DRIVEN ALTERATIONS IN INFILTRATING SUBSETS Massimo Lazzeri*, Michela Masetti, Federica Portale, Roberta Carriero, Bianca Partini, Andrea Ponzetta, Sebastien Jaillon, Piergiuseppe Colombo, Grazia Elefante, Alberto Saita, Paolo Casale, Clelia Peano, Paolo Kunderfranco, Javier Cibella, Giorgio Guazzoni, and Diletta Di Mitri Massimo Lazzeri*Massimo Lazzeri* More articles by this author , Michela MasettiMichela Masetti More articles by this author , Federica PortaleFederica Portale More articles by this author , Roberta CarrieroRoberta Carriero More articles by this author , Bianca PartiniBianca Partini More articles by this author , Andrea PonzettaAndrea Ponzetta More articles by this author , Sebastien JaillonSebastien Jaillon More articles by this author , Piergiuseppe ColomboPiergiuseppe Colombo More articles by this author , Grazia ElefanteGrazia Elefante More articles by this author , Alberto SaitaAlberto Saita More articles by this author , Paolo CasalePaolo Casale More articles by this author , Clelia PeanoClelia Peano More articles by this author , Paolo KunderfrancoPaolo Kunderfranco More articles by this author , Javier CibellaJavier Cibella More articles by this author , Giorgio GuazzoniGiorgio Guazzoni More articles by this author , and Diletta Di MitriDiletta Di Mitri More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000969.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Prostate adenocarcinoma is one of the most common cancers in the male world population and the incidence of this type of tumor has undergone a significant increase in the last decades. In recent years, research in this field has led to a greater awareness of the clinical and molecular characteristics of this tumor type. As a result, new therapeutic options have emerged to date, mainly aimed at manipulating the immune system. Here we investigated the profile of the immune composition in PCa by single cell analysis. The primary endpoint was to obtain a comprehensive profiling of the immune composition in PCa patients. Secondary endpoint was the identification of tumor-driven immune changes in the immune microenvironment that may be used in the diagnosis and prediction of progression of prostate cancer. METHODS: We conduct a single cell immune profiling strategy based on single cell RNA sequencing (scRNAseq) and multiparametric flow cytometry (FACS) in order to dissect the immune landscape of prostate cancer, both at tumor site and periphery. CD45+ immune cells infiltrating tumoral and adjacent tissues were isolated from patients with PCa and analyzed by single cell sequencing. In addition both peripheral blood and fresh tumoral tissue were collected and analyzed by FACS. RESULTS: For the scRNAseq the study included 3 patients with clinically significant prostate cancer who underwent prostatectomy (GS 4+5). Flow cytometry analysis was then extended to 45 patients bearing prostate cancer at different progression stage. Our analysis revealed a significant modulation in the abundance of several immune subsets infiltrating the tumoral tissue when compared to the non-tumoral. Furthermore we identified a subset of tumor infiltrating macrophages showing an altered gene expression profile when compared with macrophages infiltrating the non-tumoral tissue. Importantly we derived a genetic signature from this cluster of TAMs that resulted to be associated with cancer progression in human prostate cancer datasets. CONCLUSIONS: The results of our study provided a comprehensive analysis of the immune landscape in prostate cancer patients and identified tumor-driven immune changes that may be useful to develop new therapeutic strategies and for risk-stratification and decision-making process of patients. Source of Funding: AIRC foundation © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e1205-e1205 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Massimo Lazzeri* More articles by this author Michela Masetti More articles by this author Federica Portale More articles by this author Roberta Carriero More articles by this author Bianca Partini More articles by this author Andrea Ponzetta More articles by this author Sebastien Jaillon More articles by this author Piergiuseppe Colombo More articles by this author Grazia Elefante More articles by this author Alberto Saita More articles by this author Paolo Casale More articles by this author Clelia Peano More articles by this author Paolo Kunderfranco More articles by this author Javier Cibella More articles by this author Giorgio Guazzoni More articles by this author Diletta Di Mitri More articles by this author Expand All Advertisement PDF downloadLoading ...